Results Forecasts
Consolidated Earnings Forecasts
The following shows our consolidated earnings forecasts for fiscal year ending March 31, 2027. (Updated in November 2026)
- Related press release
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | |
|---|---|---|---|---|
| Net Sales | 500.0 | 550.0 | 50.0 | 10.0% |
| Operating Profit | 51.8 | 68.5 | 16.6 | 32.2% |
| Profit attributable to owners of the parent | 35.4 | 40.0 | 4.5 | 12.8% |
| Diluted earnings per share(yen) | 56.89 | 66.06 | 9.1 | 16.1% |
Sales Forecast By Destination
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | |
|---|---|---|---|---|
| Japan | 58.6 | 71.0 | 12.4 | 21.2% |
| Americas | 139.2 | 160.5 | 21.2 | 13.8% |
| EMEA | 158.0 | 175.0 | 17.0 | 11.4% |
| China | 89.4 | 81.0 | -8.4 | -9.5% |
| Asia-Pacific | 54.6 | 62.5 | 7.8 | 14.4% |
| Total | 500.0 | 550.0 | 50.0 | 9.0% |
- ※EMEA: Europe, Middle East, and Africa
Sales Forecast By Business
(billions of yen)
| Results for the Fiscal Year Ended March 31, 2026 | fiscal year ending March 31, 2027 forecasts | Change | % change | ||
|---|---|---|---|---|---|
| Diagnostics Business | Hematology | 299.4 | 330.0 | 30.6 | 10.2% |
| FCM | 4.6 | 7.5 | 2.8 | 59.9% | |
| Urinalysis | 44.0 | 50.0 | 5.9 | 13.5% | |
| Hemostasis | 72.4 | 73.0 | 0.6 | 0.8% | |
| Immunochemistry | 22.3 | 23.5 | 1.2 | 5.3% | |
| Clinical Chemistry | 2.9 | 13.0 | 10.0 | 345.5% | |
| Life Science | 24.9 | 24.0 | -0.9 | -3.8% | |
| Others | 25.9 | 25.0 | -0.9 | -3.6% | |
| Medical Robotics Business | 3.3 | 4.0 | 0.7 | 21.0% | |
| Total | 500.0 | 550.0 | 50.0 | 10.0% | |